India’s generic semaglutide surge

By Phillip Broadwith2026-04-08T09:10:00

An Indian man holds the boxes for Ozempic and Wegovy treatments

Source: © Indranil Mukherjee/AFP via Getty Images

As patents on Novo Nordisk’s diabetes and weight loss blockbusters expire, generic makers have their versions ready

Generic drugmakers in India had 20 March 2026 marked in their calendars for quite a while. That’s the date that Indian patents protecting Novo Nordisk’s semaglutide (Ozempic/Wegovy) expired. Dozens of generic versions of the drugs are now expected to enter the market, at significantly lower prices than Novo’s.